Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | OPTIMA II: de-escalating therapy in HPV-positive oropharyngeal cancer

Ari Rosenberg, MD, University of Chicago Medicine, Chicago, IL, discusses the updated results from the OPTIMA II trial (NCT03107182): a Phase II trial of chemo-immunotherapy followed by response adaptive de-escalated locoregional therapy in HPV-positive oropharyngeal cancer; chemo-immunotherapy involved nab-paclitaxel, carboplatin and anti-PD1 therapy with nivolumab. Treatment was highly effective with a 2-year progression-free survival (PFS) of 90% and a 2-year overall survival (OS) of 93%. Moreover, patients who underwent surgery after chemo-immunotherapy achieved a high pathologic complete response (pCR) rate of 67%. These findings suggest that response adaptive de-escalation is a promising de-escalation strategy in HPV-positive oropharyngeal cancer and may lead to further research on the use of anti-PD1 in the curative setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.